

Listing of Claims

STEVEN J. SARUSSI


312-913-0001

This listing of claims will replace all prior versions and  
listings of claims in the application.

(72 IS CANCELLED!)

Claims 1-187 (cancelled)

Claim 188 (new) A compound of the formula



or a pharmaceutically acceptable salt thereof wherein R<sub>1</sub> is:

A 1

(I)  $C_1-C_6$  alkyl, unsubstituted or substituted with one, two or three  $C_1-C_3$  alkyl, -F, -Cl, -Br, -I, -OH, -NH<sub>2</sub>, -C≡N, -CF<sub>3</sub>, or -N<sub>3</sub>,

(II) -(CH<sub>2</sub>)<sub>1-2</sub>-S-CH<sub>3</sub>,

(III) -CH<sub>3</sub>-CH<sub>2</sub>-S-CH<sub>3</sub>,

(IV) -CH<sub>2</sub>- (C<sub>2</sub>-C<sub>6</sub> alkenyl) unsubstituted or substituted by one -F,

(V) -(CH<sub>2</sub>)<sub>0-3</sub>- (R<sub>1</sub>-aryl) where R<sub>1</sub>-aryl is phenyl, 1-naphthyl, 2-naphthyl, indanyl, indenyl, dihydronaphthyl, tetrainyl unsubstituted or independently substituted on the aryl ring with one or two of  $C_1-C_3$  alkyl, -CF<sub>3</sub>, -F, Cl, -Br, -I,  $C_1-C_3$  alkoxy, -O-CF<sub>3</sub>, -NH<sub>2</sub>, -OH, or -C≡N;

$R_2$  is:

(I) -H,  
(II) C<sub>1</sub>-C<sub>6</sub> alkyl, or

(III)  $-(CH_2)_{0-4}-R_{2-1}$  where  $R_{2-1}$  is  $(C_3-C_6)$ cycloalkyl,  $R_{1-aryl}$  where  $R_{1-aryl}$  is optionally substituted with  $R_{100}$ , where  $R_{100}$  is

- (1)  $C_1-C_6$  alkyl,
- (2) -F, -Cl, -Br, or -I,
- (3) -OH,
- (4)  $-NO_2$ ,
- (5) -CO-OH,
- (6) -C≡N,
- (7)  $-CO-NR_{8-2}R_{8-3}$  where  $R_{8-2}$  and  $R_{8-3}$  are the same or different and are:

- (a) -H,
- (b)  $-C_1-C_6$  alkyl unsubstituted or substituted with one -OH or  $-NH_2$ ,
- (c)  $-C_1-C_6$  alkyl unsubstituted or substituted with one to three -F, -Cl, -Br, or -I,
- (d)  $-C_3-C_7$  cycloalkyl,
- (e)  $-(C_1-C_2$  alkyl)  $-(C_3-C_7$  cycloalkyl),
- (f)  $-(C_1-C_6$  alkyl) -O-  $(C_1-C_3$  alkyl),
- (g)  $-C_1-C_6$  alkenyl with one or two double bonds,
- (h)  $-C_1-C_6$  alkynyl with one or two triple bonds,
- (i)  $-C_1-C_6$  alkyl chain with one double bond and one triple bond,
- (j)  $-CO-(C_3-C_{12}$  alkyl),
- (k)  $-CO-(C_3-C_6$  cycloalkyl),
- (l)  $-CO-R_{1-heterocycle}$  where  $R_{1-heterocycle}$  is morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyrananyl, piperidinyl, tetrahydrofurananyl, or tetrahydrothiophenyl,

where the  $R_1$ -heterocycle group is bonded by any atom of the parent  $R_1$ -heterocycle group substituted by hydrogen such that the new bond to the  $R_1$ -heteroaryl group replaces the hydrogen atom and its bond, where heterocycle is unsubstituted or substituted with one or two

=O,  $C_1$ - $C_3$  alkyl, - $CF_3$ , -F, Cl, -Br, -I,  $C_1$ - $C_3$  alkoxy, - $OCF_3$ , - $NH_2$ , -OH, or - $C\equiv N$ ,

(12) - $CO-R_{N-4}$  where  $R_{N-4}$  is morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl or pyrrolidinyl where each group is unsubstituted or substituted with one or two  $C_1$ - $C_3$  alkyl,

(13) - $CO-O-R_{N-5}$  where  $R_{N-5}$  is:

(a)  $C_1$ - $C_6$  alkyl, or

(b) - $(CH_2)_{0-2}-(R_1\text{-aryl})$  where  $R_1\text{-aryl}$  is as defined above,

(14) - $SO_2-NR_{N-2}R_{N-3}$  where  $R_{N-2}$  and  $R_{N-3}$  are as defined above,

(15) - $SO-(C_1-C_6$  alkyl),

(16) - $SO_2-(C_3-C_{12}$  alkyl),

(17) - $NH-CO-O-R_{N-5}$  where  $R_{N-5}$  is as defined above,

(18) - $NH-CO-N(C_1-C_3$  alkyl)<sub>2</sub>,

(19) - $N-CS-N(C_1-C_3$  alkyl)<sub>2</sub>,

(20) - $N(C_1-C_3$  alkyl)- $CO-R_{N-5}$  where  $R_{N-5}$  is as defined above,

(21) - $NR_{N-2}R_{N-3}$  where  $R_{N-2}$  and  $R_{N-3}$  can be the same or different and are as defined above,

(22) - $R_{N-4}$  where  $R_{N-4}$  is as defined above,

(23) - $O-CO-(C_1-C_6$  alkyl),

(24) - $O-CO-N(C_1-C_3$  alkyl)<sub>2</sub>,

(25) - $O-CS-N(C_1-C_3$  alkyl)<sub>2</sub>.

- (26) -O-(C<sub>1</sub>-C<sub>6</sub> alkyl),
- (27) -O-(C<sub>2</sub>-C<sub>5</sub> alkyl)-COCH<sub>3</sub>,
- (28) -S-(C<sub>1</sub>-C<sub>6</sub> alkyl),
- (29) C<sub>1</sub>-C<sub>6</sub> alkyl unsubstituted or substituted with 1, 2, 3, 4, or 5 -F,
- (30) -O-(C<sub>1</sub>-C<sub>6</sub> alkyl unsubstituted or substituted with 1, 2, 3, 4, or 5 -F, or
- (31) -O- $\phi$ ,

R<sub>n-1</sub> is phenyl that is independently substituted with one, two, three or four of R<sub>100</sub>;

R<sub>a</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sub>c</sub> is

R<sub>cX</sub> where R<sub>cX</sub> is morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, or tetrahydrothiophenyl, each of which is optionally substituted with oxo, C<sub>1</sub>-C<sub>3</sub> alkyl, -CF<sub>3</sub>, -F, Cl, -Br or -I, C<sub>1</sub>-C<sub>3</sub> alkoxy, -O-CF<sub>3</sub>, -NH<sub>2</sub>, -OH, or -C≡N;

R<sub>cY</sub> where R<sub>cY</sub> is pyridinyl, pyrimidinyl, quinolinyl, indenyl, indanyl, benzothiophenyl, indolyl, indolinyl, pyridazinyl, pyrazinyl, isoindolyl, isoquinolyl, quinazolinyl, quinoxalinyl, ~~thalazinyl, idazolyl,~~ isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, indolizinyl, indazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, furanyl, thienyl, pyrrolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, 1, 4-benzodioxanyl, purinyl, oxazolopyridinyl, imidazopyridinyl, isothiazolyl, naphthyridinyl, cinnolinyl, carbazolyl,  $\beta$ -carbolinyl,

isochromanyl, chromanyl, furazanyl,  
 tetrahydroisoquinoline, isoindolinyl,  
 isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl,  
 isobenzothiophenyl, benzoxazolyl, or pyridopyridinyl,  
 each of which is optionally substituted with  $C_1$ - $C_3$  alkyl,  
 $-CF_3$ ,  $-F$ ,  $Cl$ ,  $-Br$ , or  $I$ ,  $C_1$ - $C_3$  alkoxy,  $-O-CF_3$ ,  $-NH_2$ ,  $-OH$ ,  
 or  $-C\equiv N$ ;  
 $-(C_1-C_{10})$  alkyl- $R_{CH}$ ; or  
 $-(C_1-C_{10})$  alkyl- $R_{CH}$ .

Claim 189 (new) A compound according to claim 172, which is  $N$ -[(1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-<sup>(188)</sup>  
 (piperidine-1-carbonyl)-hexyl]- $N,N$ -dipropyl-isophthalamide.

Claim 190 (new) A compound according to claim 172, which is  $N$ -[(1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-(2-<sup>(188)</sup>  
 morpholin-4-yl-ethylcarbamoyl)-pentyl]-5-methyl- $N,N$ -dipropyl-  
 isophthalamide.

Claim 191 (new) A compound according to claim 172, which is  $N$ -[(1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-<sup>(188)</sup>  
 [(tetrahydro-furan-2-ylmethyl)-carbamoyl]-pentyl]-5-methyl- $N,N$ -  
 dipropyl-isophthalamide.

Claim 192 (new) A compound according to claim 172, which is  $N$ -[(1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-methyl-5-<sup>(188)</sup>  
 morpholin-4-yl-5-oxo-pentyl]-5-methyl- $N,N$ -dipropyl-  
 isophthalamide.

Claim 193 (new) A compound according to claim 172, which is  $N$ -[(1-(S)-(3,5-Difluoro-benzyl)-4-(R)-[(furan-2-ylmethyl)-<sup>(188)</sup>

carbamoyl]-2-(S)-hydroxy-pentyl)-5-methyl-N,N-dipropyl-isophthalamide.

194. (new) A pharmaceutical composition comprising a compound according to claim 188 in combination with a pharmaceutically acceptable carrier.

*A1*  
H1B2  
2T  
10/6/04

195. (new) A method according of treating ~~or preventing~~ Alzheimer's Disease comprising administering to a subject in need of such treatment an effective amount of a compound according to claim 188.